1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. North America Vaccine Adjuvants Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. North America Vaccine Adjuvants Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. North America Vaccine Adjuvants Market Country Analysis
6.2 North America Vaccine Adjuvants Market Revenue 2020-2030 (US$ Million)
6.3 North America Vaccine Adjuvants Market Forecast Analysis
7. North America Vaccine Adjuvants Market Analysis – by Adjuvant Class
7.1 Mineral Salt Adjuvant
- 7.1.1 Overview
- 7.1.2 Mineral Salt Adjuvant: North America Vaccine Adjuvants Market – Revenue and Forecast, 2020-2030 (US$ Million)
7.2 Emulsion Adjuvant
- 7.2.1 Overview
- 7.2.2 Emulsion Adjuvant: North America Vaccine Adjuvants Market – Revenue and Forecast, 2020-2030 (US$ Million)
7.3 Liposome Adjuvant
- 7.3.1 Overview
- 7.3.2 Liposome Adjuvant: North America Vaccine Adjuvants Market – Revenue and Forecast, 2020-2030 (US$ Million)
8. North America Vaccine Adjuvants Market Analysis – by Type
8.1 Human Vaccine Adjuvant
- 8.1.1 Overview
- 8.1.2 Human Vaccine Adjuvant: North America Vaccine Adjuvants Market – Revenue and Forecast, 2020-2030 (US$ Million)
8.2 Veterinary Vaccine Adjuvant
- 8.2.1 Overview
- 8.2.2 Veterinary Vaccine Adjuvant: North America Vaccine Adjuvants Market – Revenue and Forecast, 2020-2030 (US$ Million)
9. North America Vaccine Adjuvants Market – North America (US, Canada, Mexico) Analysis
9.1 North America (US, Canada, Mexico)
- 9.1.1 North America (US, Canada, Mexico): North America Vaccine Adjuvants Market – Revenue
and Forecast to 2030 (US$ Million)
- 9.1.1.1 North America (US, Canada, Mexico):
North America Vaccine Adjuvants Market Breakdown, by Adjuvant Class
- 9.1.1.2 North America (US, Canada, Mexico):
North America Vaccine Adjuvants Market Breakdown, by Type
10. Competitive Landscape
10.1 Heat Map Analysis
10.2 Company Positioning and Concentration
11. Industry Landscape
11.1 Overview
11.2 Market Initiative
11.3 Partnerships and Collaborations
11.4 Other Developments
12. Company Profiles
12.1 Croda International Plc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 CSL Ltd
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Dynavax Technologies Corp
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 GSK Plc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Hawaii Biotech Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 InvivoGen SAS
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Novavax Inc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Phibro Animal Health Corp
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Seppic SA
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 SPI Pharma Inc
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
13. Appendix
13.1 About Business Market Insights
13.2 List of Abbreviations